Abbott Laboratories - Product Pipeline Review - 2012

Summary

“Abbott Laboratories - Product Pipeline Review - 2012” provides data on the Abbott Laboratories’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Abbott Laboratories’s corporate website, SEC filings, investor presentations and featured press releases, both from Abbott Laboratories and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Abbott Laboratories - Brief Abbott Laboratories overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Abbott Laboratories human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Abbott Laboratories with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Abbott Laboratories’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Abbott Laboratories’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Abbott Laboratories in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Abbott Laboratories’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Abbott Laboratories.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Abbott Laboratories and identify potential opportunities in those areas.

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 10
Abbott Laboratories Snapshot 11
Abbott Laboratories Overview 11
Key Information 11
Key Facts 11
Abbott Laboratories – Research and Development Overview 12
Key Therapeutic Areas 12
Abbott Laboratories – Pipeline Review 21
Pipeline Products by Stage of Development 21
Pipeline Products – Monotherapy 22
Pipeline Products – Combination Treatment Modalities 23
Abbott Laboratories – Pipeline Products Glance 24
Abbott Laboratories – Late Stage Pipeline 24
Abbott Laboratories Clinical Stage Pipeline Products 27
Abbott Laboratories – Early Stage Pipeline Products 35
Abbott Laboratories – Drug Profiles 36
ABS-103R 36
ABT-072 38
ABT-072 + PegIFN + Ribavirin 39
ABT-110 41
ABT-122 42
ABT-126 43
ABT-199 45
ABT-199 + Bendamustine + Rituximab 47
ABT-199 + Rituximab 49
ABT-263 + Bendamustine + Rituximab 51
ABT-263 + Erlotinib 53
ABT-263 + Etoposide + Cisplatin 54
ABT-263 + Fludarabine + Cyclophosphamide + Rituximab 55
ABT-263 + Gemzar 57
ABT-263 + Irinotecan 58
ABT-263 + Paclitaxel 59
ABT-263 + Rituximab 60
ABT-263 + Taxotere 61
ABT-267 62
ABT-267 + Peginterferon Alpha-2a + Ribavirin 63
ABT-288 65
ABT-308 66
ABT-333 67
ABT-333 + PegIFN + Ribavirin 68
ABT-348 70
ABT-348 + Azacitidine 71
ABT-348 + Carboplatin 72
ABT-348 + Docetaxel 74
ABT-354 75
ABT-363 76
ABT-384 77
ABT-413 78
ABT-436 79
ABT-450 80
ABT-450 + ABT-267 + Ritonavir + Pegylated Interferon Alpha-2a + Ribavirin 81
ABT-450 + Ritonavir + ABT-072 + Ribavirin 83
ABT-450 + Ritonavir + ABT-267 85
ABT-450 + Ritonavir + ABT-333 + Ribavirin 86
ABT-450 + Ritonavir + PegIFN + Ribavirin 88
ABT-560 90
ABT-614 91
ABT-639 92
ABT-652 93
ABT-700 94
ABT-700 + Capecitabine + Oxaliplatin 95
ABT-700 + Erlotinib 97
ABT-767 99
ABT-806 100
ABT-869 + Carboplatin + Paclitaxel 101
ABT-888 + Carboplatin + Gemcitabine 103
ABT-888 + Carboplatin + Paclitaxel 105
ABT-957 107
ABT-981 108
ABT-SLV361 109
ABT450 + Ritonavir 110
adalimumab 111
AP-214 113
atrasentan hydrochloride 115
briakinumab 116
daclizumab 118
Duodopa 120
elagolix 122
elotuzumab 124
Elotuzumab + Bortezomib + Dexamethasone 126
Elotuzumab + Lenalidomide + Dexamethasone 128
enavatuzumab 130
H224-G11 131
Humira + Prednisone 132
Humira + Prednisone + Azathioprine 133
Isentress + Kaletra 135
linifanib 136
navitoclax 138
SLV-337 140
sofinicline 141
tebanicline tosylate 143
testosterone 145
veliparib 146
Veliparib + Capecitabin + Radiation Therapy 147
Veliparib + FOLFIRI 148
Veliparib + Temodar 149
Vicodin CR 151
Volociximab 153
Abbott Laboratories – Pipeline Analysis 155
Abbott Laboratories – Pipeline Products by Therapeutic Class 155
Abbott Laboratories – Pipeline Products By Target 156
Abbott Laboratories – Pipeline Products by Route of Administration 157
Abbott Laboratories – Pipeline Products By Mechanism of Action 158
Abbott Laboratories – Recent Pipeline Updates 159
Abbott Laboratories - Dormant Projects 177
Abbott Laboratories - Discontinued Pipeline Products 182
Discontinued Pipeline Product Profiles 182
Abbott Laboratories – Company Statement 186
Abbott Laboratories – Locations And Subsidiaries 188
Head Office 188
Other Locations & Subsidiaries 188
Abbott Laboratories - Key Manufacturing Facilities 198
Abbott Laboratories, Recent Developments 199
Abbott Laboratories- Press Release 199
Financial Deals Landscape 244
Abbott Laboratories, Deals Summary 244
Abbott Laboratories, Pharmaceuticals & Healthcare, Deal Details 251
Asset Transactions 251
Venture Financing 257
Partnerships 267
Licensing Agreements 381
Equity Offering 416
Debt Offering 420
Asset Transactions 447
Acquisition 469
Appendix 507
Methodology 507
Coverage 507
Secondary Research 507
Primary Research 507
Expert Panel Validation 507
Contact Us 508
Disclaimer 508

List of Tables
Abbott Laboratories, Key Information 22
Abbott Laboratories, Key Facts 22
Abbott Laboratories – Pipeline by Indication, 2012 26
Abbott Laboratories – Pipeline by Stage of Development, 2012 32
Abbott Laboratories – Monotherapy Products in Pipeline, 2012 33
Abbott Laboratories – Combination Treatment Modalities in Pipeline, 2012 34
Abbott Laboratories – Filed, 2012 35
Abbott Laboratories – Filing Rejected/Withdrawn, 2012 36
Abbott Laboratories – Phase III, 2012 37
Abbott Laboratories – Phase II, 2012 38
Abbott Laboratories – Phase I, 2012 42
Abbott Laboratories – Pre-Clinical, 2012 46
Abbott Laboratories – Pipeline By Therapeutic Class, 2012 166
Abbott Laboratories - Pipeline By Target, 2012 167
Abbott Laboratories – Pipeline By Route of Administration, 2012 168
Abbott Laboratories – Pipeline Products By Mechanism of Action, 2012 169
Abbott Laboratories – Recent Pipeline Updates, 2012 170
Abbott Laboratories - Dormant Developmental Projects,2012 188
Abbott Laboratories - Discontinued Pipeline Products, 2012 193
Abbott Laboratories, Other Locations 199
Abbott Laboratories, Subsidiaries 200
Abbott Laboratories, Key Manufacturing Facilities 209
Abbott Laboratories, Deals Summary 255
Abbott Labs Acquires AP214 From Action Pharma For $110 Million 262
Abbott Labs Completes The Acquisition Of Healthcare Solutions Business From Piramal Healthcare 264
Abbott Labs Acquires Vascular Business Of Guidant From Boston Scientific 266
AM-Pharma Secures $39.7 Million In Series D Financing 268
Enlight Biosciences Secures $13 Million In Financing 271
Evalve Secures $60 Million In Series D Financing 272
Ovalis Secures $6.6 Million In Series B Funding 274
Optobionics Secures $5 Million In Series D-1 Financing 276
Abbott Enters Into Licensing Agreement With Stanford University For Prostate Cancer Biomarkers 278
Insulet Amends Licensing Agreement With Abbott Diabetes 280
Insulet Amends Licensing Agreement With Abbott Diabetes Care 281
Insulet Amends Licensing Agreement With Abbott Diabetes Care 282
LGC Enters Into Licensing Agreement With Abbott Labs 283
Fujirebio Diagnostics Signs Licensing Agreement With Abbott Labs 284
Rubicon Genomics Enters Into An Agreement With Abbott Labs 285
Liquidia Technologies Signs Collaboration And License Agreement With Abbott 286
Epigenomics Expands And Amends Licensing Agreement With Abbott Molecular 287
Alcon Enters Into Licensing Agreement With Advanced Medical Optics 288
Advanced Medical Optics Enters Into Licensing Agreement With Alcon 289
Insulet Amends Licensing Agreement With Abbott Diabetes Care 290
Advanced Medical Optics Enters Into Licensing Agreement With Bausch & Lomb 291
SkyePharma Amends Licensing Agreement With Abbott 292
Advanced Medical Optics Signs An Agreement With Carl Zeiss Meditec 293
Epigenomics Signs An Agreement With Abbott Labs 294
MacroArray Technologies Enters Into A License Agreement With Abbott 295
Abbott Labs Enters Into Licensing Agreement With Advanced Life Science Institute 296
Dade Behring Enters Into Licensing Agreement With Abbott Diagnostics 297
Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 298
ChemDiv Research Institute Enters Into Co-Development Agreement With Abbott Labs 299
biOasis Technologies Enters Into Research Agreement With Abbott Labs 300
Abbott India Enters Into Joint Venture Agreement With Syngene International 301
Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 303
Abbott Vascular Enters Into Co-Marketing Agreement With St. Jude Medical 304
Abbott Enters Into Co-Development Agreement With Genetics Lab For Molecular Assay Development 306
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 307
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 309
Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 311
Abbott Labs Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals 312
Abbott Labs Enters Into Co-Development Agreement With Yeda Research 313
Abbott Labs Enters Into Co-Development Agreement With Biotest For BT-061 314
Biofortuna Enters Into Distribution Agreement With Abbott 316
Seattle Genetics Enters Into Collaboration With Abbott 317
Intelligent Medical Devices Enters Into An Agreement With Abbott Labs 318
Partners In Health Forms Joint Venture With Abbott Labs And Abbott Fund 319
EpiTherapeutics Enters Into Co-Development Agreement With Abbott 321
STRATEC Biomedical Enters Into An Agreement With Abbott Diagnostics 322
QIAGEN Enters Into An Agreement With Abbott 323
Abbott Enters Into An Agreement With Reata Pharma 324
Celera Enters Into Distribution Agreement With Abbott Labs 326
TearLab Enters Into An Agreement With AMO Canada 328
Asahi Intecc Enters Into Distribution Agreement With Abbott Labs For PTCA Guidewires 329
Abbott Labs Enters Into Co-Development Agreement With Neurocrine Biosciences 330
Axis-Shield Enters Into An Agreement With Abbott Labs 332
BG Medicine Expands Co-Development Agreement With Abbott Labs 333
Abbott Labs Enters Into An Agreement With GlaxoSmithKline 334
Biogen Idec Amends Its Agreement With Facet Biotech 335
Abbott Labs Enters Into An Agreement With BG Medicine 339
Coherex Medical Enters Into Distribution Agreement With Abbott Labs 340
Facet Biotech Enters Into Co-Development Agreement With Trubion Pharma 341
Abbott Labs Enters Into Co-Development Agreement With Pfizer 343
Luminex Molecular Amends Distribution Agreement With Abbott Labs 344
Abbott Labs Enters Into Co-Development Agreement With GlaxoSmithKline 345
AstraZeneca Enters Into Co-Promotion Agreement With Abbott 346
HUYA Bioscience Enters Into Co-Development Agreement With Abbott 348
Health Discovery Signs An Agreement With Abbott Labs 349
Axis-Shield Enters Into Co-Development Agreement With Abbott 350
Celera Enters Into Research Agreement With Abbott 351
Celera Enters Into An Agreement With Abbott Labs 352
Abbott Labs Extends Its Distribution Agreement With Axis-Shield 353
Smiths Medical Enters Into An Agreement With Abbott Labs 354
Abbott Labs Enters Into Agreement With Genentech, OSI And Roche 355
Luminex Enters Into Co-Marketing Agreement With Abbott Labs 357
Abbott Labs, Genentech And WEHI Enter Into Co-Development Agreement 358
Angioblast Systems Enters Into A Co-Development Agreement With Abbott India 359
Abbott Labs Signs An Agreement With Medica 360
Gene Logic Enters Into Co-Development Agreement With Solvay Pharma 361
Genentech Enters Into Co-Development Agreement With Abbott 362
Abbott And Caprion Extend Partnership To Discover Antibody Targets For Cancer 363
Gene Logic Enters Into Co-Development Agreement With Abbott 364
Axis-Shield UK Enters Into An Agreement With Abbott Diagnostics 365
Eisai Amends Co-Marketing Agreement With Abbott 366
Asahi Intecc Extends Distribution Agreement With Abbott For PTCA Guidewires In European Union 373
Shire Enters Into Co-Promotion Agreement With Abbott Labs 374
BioView Enters Into An Agreement With Abbott Molecular 375
Abbott Labs Enters Into Agreement With Enanta Pharma 376
SciGen Enters Into Co-Marketing Agreement With Abbott Labs 377
Abbott Labs Enters Into Distribution Agreement With Verax 378
Par Pharma Enters Into Co-Promotion Agreement With Solvay Pharma For Androge 379
Oscient Pharma Enters Into Co-Marketing Agreement With Abbott Canada 381
Abbott Labs Enters Into Agreement With Dharmacon 382
AstraZeneca Enters Into Agreement With Abbott Labs 383
Asahi Intecc Extends Distribution Agreement With Abbott For PTCA Guidewires In US 389
Innogenetics Extends Research Agreement With Solvay Pharma 390
Myriad Genetics Enters Into Co-Development Agreement With Abbott Labs 391
Kowa Company Enters Into Licensing Agreement With Abbott 392
Innogenetics Enters Into Licensing Agreement With Abbott Labs 393
Crucell Enters Into License Agreement With Abbott 394
Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 395
Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 397
Abbott Labs Enters Into Licensing Agreement With Reata Pharma 398
Abbott Labs Enters Into Licensing Agreement With Pfizer 399
Lupin Enters Into Patent Licensing Agreement With Abbott For Antara 400
Pronova BioPharma Extends Its Licensing Agreement With Abbott Products Operations For Omacor 401
Abbott Enters Into Licensing Agreement With Zydus Cadila 403
Abbott Labs Enters Into Licensing Agreement With Laboratoires Pierre Fabre 404
PanGenetics Enters Into Licensing Agreement With Abbott 406

List of Figures
Abbott Laboratories – Pipeline by Indication, 2012 26
Abbott Laboratories – Pipeline by Stage of Development, 2012 32
Abbott Laboratories – Monotherapy Products in Pipeline, 2012 33
Abbott Laboratories – Combination Treatment Modalities in Pipeline, 2012 34
Abbott Laboratories – Pipeline By Therapeutic Class, 2012 166
Abbott Laboratories - Pipeline By Target, 2012 167
Abbott Laboratories – Pipeline By Route of Administration, 2012 168